A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine ...
4hon MSN
Nebraska Hematology Oncology becomes state’s only trial site for new prostate cancer treatment
The treatment, called Pasritamig, teaches the immune system's T cells to target and attack cancer cells in the prostate.
A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...
A urologist explains the options and warns that ignoring an enlarged prostate could lead to permanent bladder damage.
New technologies can potentially save lives by helping identify prostate cancer earlier, and transforming the way doctors ...
Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of ...
The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...
Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...
Morning Overview on MSN
A targeted drug won approval for a hard-to-treat form of advanced prostate cancer
Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...
Morning Overview on MSN
Capivasertib won FDA approval for a hard-to-treat form of prostate cancer
Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results